Discontinuation report SYNAGIS
| Report ID | 257874 |
| Drug Identification Number | 02438364 |
| Brand name | SYNAGIS |
| Common or Proper name | Nom commun ou nom propre |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | PALIVIZUMAB |
| Strength(s) | 100MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | Taille de l’emballage |
| ATC code | J06BD |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2020-01-01 |
| Remaining supply date | |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Renseignements sur l’approvisionnement restant - EN |
| Company comments | Commentaires de l’entreprise - EN |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. Veuillez contacter le Service d'information médicale d'AstraZeneca Canada pour toute question spécifique au 1-800-668-6000 (EN) ou au 1-800-461-3787 (FR) ou par courriel : [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-12-04 | French | Compare |
| v3 | 2025-12-04 | English | Compare |
| v2 | 2025-12-04 | French | Compare |
| v1 | 2025-12-04 | English | Compare |
Showing 1 to 4 of 4